Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04879849 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT04879849 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 34 participants.
The verdict
NCT04879849, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
In this study, adults with non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and squamous-cell carcinoma of the head and neck (SCCHN) will be treated with TAK-676 and pembrolizumab following radiotherapy. The main aims of this study are to check if people are improving after treatment with TAK-676, getting side effects from these combined treatments, and how much TAK-676 people with these cancers can receive without getting unacceptable side effects from it. Participants will receive radiotherapy, then at least 40 hours later will receive pembrolizumab followed by TAK-676 slowly through a vein (infusion). Participants will receive an infusion of pembrolizumab at the same dose every 3 weeks. Different small groups of participants will receive lower to higher doses of TAK-676 on specific days of a 21-day cycle. This study will be happening at sites in North America.
Interventions
- DRUG Pembrolizumab
- DRUG TAK-676
- RADIATION Image-guided radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2021-09-09 |
| Est. Completion | 2024-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04879849
The ClinicalTrials.gov registry entry for NCT04879849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04879849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04879849 about?
NCT04879849 is a clinical study titled "A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers". In this study, adults with non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and squamous-cell carcinoma of the head and neck (SCCHN) will be treated with TAK-676 and pembrolizumab following radiotherapy. The main aims of this study are to check if people are improving after t...
What is the current status of trial NCT04879849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2021-09-09. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT04879849?
The interventions under investigation include: Pembrolizumab (DRUG), TAK-676 (DRUG), Image-guided radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT04879849?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.